Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539500 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00539500: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00539500 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00539500, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied. Finally, researchers want to learn if collecting the cells with the CliniMACS device can decrease the possibility of tumor cells contaminating (appearing in) the stem cells that are reinfused into participants.
Primary Outcome
Engraftment Failure Rate is number of participants with engraftment failure out of total participants. Engraftment failure is defined as failure to achieve an absolute neutrophil count (ANC) \>500/ul by day 42, and has no evidence of donor chimerism on bone marrow examination.
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Etoposide
- PROCEDURE Stem Cell Infusion
- DEVICE ClinicMACS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-09-05 |
| Phase | Phase 2 |
Why NCT00539500 stopped before completion
NCT00539500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00539500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00539500 about?
NCT00539500 is a clinical study titled "Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma". The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied. Finally, researchers want to learn if collecting the cells with the CliniMACS device can decrease the pos...
What is the current status of trial NCT00539500?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-10. Estimated completion is 2012-09-05.
What interventions are being tested in trial NCT00539500?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Etoposide (DRUG), Stem Cell Infusion (PROCEDURE), ClinicMACS (DEVICE).
Who is sponsoring clinical trial NCT00539500?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00539500's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia